

## **BRIEF CURRICULUM VITAE**

### **MARIA STANGO, MD, PhD**

**Associate Professor of Nephrology**  
**School of Medicine, Faculty of Health Sciences,**  
**Aristotle University of Thessaloniki, Greece**  
**Department of Nephrology,**  
**Hippokration General Hospital,**  
**49 Konstantinoupoleos Str, 54642**  
**Thessaloniki**

**Email: [mstangou@auth.gr](mailto:mstangou@auth.gr)**

**Tel: 2310992877, 6944820624**

**Website: [www.mstangou.gr](http://www.mstangou.gr)**

## **EDUCATION**

Aristotle University of Thessaloniki (AUT),Greece 1984-1990

M.D, Honours: 8/10, July 1990

Ph.D. in Nephrology 1997-2002

Aristotle University of Thessaloniki, Greece

Title:

Pathogenetic Mechanisms in IgA Nephropathy. The therapeutic role of polyunsaturated fatty acids.

## **INTERNSHIP AND RESIDENCY**

"Saint Dimitrios" General Hospital, Thessaloniki, Greece

Division of Internal Medicine

General professional training in Internal Medicine 1990-1992

Royal Postgraduate Medical School, Hammersmith Hospital,  
Department of Nephrology, London, UK

Southmead Hospital

The Richard Bright Renal Unit, Bristol, UK 1993-1994

Hippokration Hospital

Department of Nephrology, Thessaloniki, Greece 1994-1997

### **CAREER STATEMENT**

Consultant Nephrologist in the Department of Nephrology, "G. Papanikolaou"  
Hospital, Thessaloniki 1999-2003

Consultant Nephrologist in the Department of Nephrology AUTH, "Hippokration"  
General Hospital, Thessaloniki 2003-2013

Lecturer in Nephrology AUTH 2013-2015

Assistant Professor in Nephrology AUTH 2015-2020

Associate Professor in Nephrology Since October 2020

### **CURRENT APPOINTMENT**

Department of Nephrology, Aristotle University of Thessaloniki, Hippokration  
Hospital

Associate Professor in Nephrology since October 2020

#### **SCHOLARSHIPS, AWARDS**

- Eight month Scholarship of the Greek Renal Association, Clinical Research Fellow, Imperial College London, Hammersmith Hospital
- "Efstathios Alexopoulos" award: 2012 for "Cytokine activity in primary IgA nephropathy may be affected after steroid and azathioprine treatment"

#### **PROFESSIONAL MEMBERSHIPS**

Greek Medical Association, (Thessaloniki), since October 1990  
General Medical Council, UK (Ref No 3701311) since February 1993

#### **MEDICAL LICENCURE**

Licensed in Greece since October 1990  
Licensed in United Kingdom since February 1993

#### **RESEARCH ACTIVITIES**

- Basic and Experimental Nephrology (Pathogenesis of glomerular diseases, Biomarkers in glomerulonephritis, Genetic studies in primary glomerulonephritis, Progression of renal damage)
- Clinical Nephrology (Renal pathology, Treatment of primary glomerulonephritis, vasculitis and systemic diseases)

- Chronic Renal Failure
- Senescence and Immunosenescence in Chronic Kidney Disease and Renal Transplantation

## **MULTICENTRE EUROPEAN AND INTERNATIONAL RESEARCH PROGRAMMES**

1. "Chronic Inflammation leading to scarring, the major mechanism leading to scarring" organized by the University of Aberdeen, in collaboration with 13 different Universities in Europe (Biomed-2 Programme of European Union 2000-2003)
2. Prospective Immunogenicity Surveillance Registry (PRIMS). EPO-ANE-4014 phase IV from 15/11/2012 to 31/10/2014
3. "Elucidating IgA nephropathy through genetic studies of IgA1 glycosylation", University of Birmingham, Alabama
4. European validation study of the Oxford classification of IgA nephropathy —VALIGA study, ERA-EDTA
5. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomized controlled trial (PEXIVAS study), Cambridge University Hospitals NHS Foundation Trust, UK, EUDRACT number:2009-013220-24 ISRCTN number: ISRCTN07757494
6. Post VALIGA studies
7. A genome-wide association study (GWAS) for severity and progression of IgA nephropathy
8. Interferon-regulated immunoproteasome: genetic conditioning, lymphomonocyte expression, correlation with clinical and pathology data and progression of IgA nephropathy
9. Role of soluble CD71 and CD89 as new biomarkers in IgA nephropathy and Henoch-Schonlein Purpura nephritis.
10. Genetic Studies of Chronic Kidney Disease Columbia University
  - a. Medical Centre, Protocol: IRB-AAAC7385 (YIIMOO)
11. Ferric Carboxymaltose Assessment in Subjects with Iron Deficiency Anaemia and Non-dialysis-dependent CKD (FIND-CKD). Phase IV from 01/09/2010 to 04/07/2013
12. Post-Authorization Safety Cohort observation of Retacrit (epoetin zeta) administered subcutaneously for the treatment of renal anemia (PASCO II). Hospira Inc, EPOE 09-11 Phase IV start 06/11/2012 on going.S.I.

13. An observation study of the response to Epoetin Theta (Eporatio) as well as of clinical and inflammatory factors influencing treatment responsiveness in dialysis and predialysis patients with kidney related anemia in the real world practice in Greece, REPORT study. Teva Pharmaceuticals Hellas SA, TV 44687 ONC40063. Phase IV start 3/12/2014 on going P.I.
14. Observational Study of Correction of Anaemia with Darbepoetin Alfa at Monthly Dose Frequency in EU and Australian Patients with Chronic Kidney Disease not on Dialysis, ADAPTATION study. Amgen Ltd, 20130301. Phase IV start 19/11/2014 on going s.l.
15. A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis
16. A randomize. double-blind, placebo-controlled, parallel-group, multicenter, eventdriven phase III study to investigate the safety and efficacy of finerenone, in addition to standard of care, on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
17. A randomize. double-blind, placebo-controlled study to evaluate efficacy and safety of Nefecon in patients with primary IgA Nephropathy at risk of progressing to End Stage Renal Disease (NeflgArd)
18. "Multicenter non-interventional post-authorization safety study (Nt-PASS) to monitor the incidence of relevant drug-related adverse events and epoetinrelated lack of efficacy among CKD patients receiving s.c. Binocrit@ or Epoetin Alfa Hexal@

## **SCIENTIFIC PUBLICATIONS**

- Author of 46 scientific publications reported by Pub-Med and 3 publications not in Pub-Med.
- Participate in more than 250 studies published in abstract form or announced in international congresses, or national meetings.
- Author in 10 chapters in books, including Internal Medicine, Pathophysiology, Renal Transplantation

## **EDITORIAL**

- Debuty Editor in Hellenic Nephrology
- Editorial Board of Biomed Research International, J Clin Nephrol Kidney Dis, ProbeUrology & Nephrology, Immunology Letters.

**CITATION INDEX: 884**  
**IMPACT FACTOR: 115.7**  
**H-Index: 14**

## **PUBLICATIONS**

1. Sampani E, Daikidou DV, Lioulios G, et al. CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus. *Int J Mol Sci* 2021;22(6):2975. doi: 10.3390/ijms22062975. PMID: 33804135
2. Lioulios G, Fylaktou A, Papagianni A, Stangou M. T cell markers recount the course of immunosenescence in healthy individuals and chronic kidney disease. *Clin Immunol* 2021;225:108685. doi: 10.1016/j.clim.2021.108685. Epub 2021 Feb 4. PMID: 33549833 Review.
3. Canney M, Barbour SJ, Zheng Y, et al. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. *J Am Soc Nephrol* 2021;32(2):436-447. doi: 10.1681/ASN.2020030349. Epub 2020 Dec 23. PMID: 33514642
4. Cox SN, Chiurlia S, Divella C, et al. Formalin fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy. *Sci Rep* 2020;doi: 10.1038/s41598-020-72026
5. Bantis K, Stangou M, Kalpakidis S, et al. Systemic complement activation in anti-neutrophil cytoplasmic antibody- associated vasculitis and necrotizing glomerulonephritis. *Nephrology (Carlton)*. 2020 Jun 29. doi: 10.1111/nep.13747. Online ahead of print. PMID: 32602136
6. Schena FP, Anelli VW, Trotta J, et al. Development and testing of an artificial intelligence tool for predicting end stage kidney disease in patients with immunoglobulin A nephropathy. *Kidney Int*. 2020 Sep 1:S00852538(20)30969-8.doi: 10.1016/j.kint.2020.07.046.
7. Bantis K, Stangou M, Kalpakidis S, et al. Systemic complement activation in anti-neutrophil cytoplasmic antibody-associated vasculitis and necrotizing glomerulonephritis. *Nephrology (Carlton)*. 2020 Jun 29:e13747. doi: 10.1111/nep.13747.
8. Lioulios G, Stangou M, Sarafidis PA, et al. Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis

- Patients. *Blood Purif.* 2020 Feb 12;1-8. doi: 10.1159/000505432. Online ahead of print. PMID: 32050202
9. Stangou M, Marinaki S, Papachristou E, et al. Immunosuppressive regimens based on Cyclophosphamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy. *PLOS One.* 2019 Aug 12;14(8):e0217116. doi: 10.1371/journal.pone.0217116. eCollection 2019. PMID: 31404062
  10. Stangou MJ, Marinaki S, Papachristou E, et al. Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients. *Histopathology.* 2019 doi:
  11. Provatopoulou S, Kalavrizioti D, Stangou M, et al. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study. *Rom J Intern Med.* 2019 Jun 1;57(2):141-150. doi: 10.2478/rjim-2018-0044. PMID: 30864406
  12. Coppo R, D'Arrigo G, Tripepi G, et al. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. *Nephrol Dial Transplant.* 2020 Jun 1;35(6):1002-1009. doi: 10.1093/ndt/gfy302. PMID: 30418652
  13. Coppo R, Peruzzi L, Loiacono E, et al. Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy. *Nephrol Dial Transplant.* 2019 Apr 1;34(4):587-596. doi: 10.1093/ndt/gfy064.
  14. Stangou M, Spartalis M, Daikidou DV, et al. Impact of Th1 and Th2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease. *J Nephrol* 2017;6(3):187-195
  15. Stangou M, Papatotiriou M, Xydakis D, et al. IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology. *Clin Kidney J* 2018;sfx076, <https://doi.org/10.1093/ckj/sfx076>
  16. Stangou M, Bantis C, Skoularopoulou M, et al. Th1, Th2 and Treg/T17 cytokines in two types of proliferative glomerulonephritis. *Indian J Nephrol* 2016;26:159-166
  17. Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia. The MEST score provides earlier risk prediction in IgA nephropathy. *Kidney Int* 2016;89:167-175

18. Sambani E, Toulkeridis G, Stangou M, et al. Diabetic Patient with Fungal Renal Infection and Fungus Balls: Case Study. *J Clin Nephrol Kidney Dis* 2017;2:1006
19. Daikidou D-V, Stangou M. Biomarkers in the differential diagnosis of podocytopathies. *J Clin Nephrol Kidney Dis* 2016;1(1):1003
20. Feehally J, Coppo R, Troyanov S, et al. Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy. *Nephron* 2016;132(1):15-24.
21. Serino G, Pesce F, Sallustio F, et al. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. *Kidney Int* 2016;89:683-692
22. Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. *Kidney Int* 2014;86(4):828-36
23. Stangou M, Papagianni A, Bantis C, et al. Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine. *Clin Nephrol* 2013;80(3):203-10.
24. Tesar V, Troyanov S, Coppo R, et al. Corticosteroids in IgA nephropathy: What determines the response? Lessons from the VALIGA study. *J Am Soc Nephrol* 2015;26(9):2248-58.
25. Stangou M, Papagianni A. Urinary cytokines as biomarkers in glomerular diseases. *Recent Patents on Biomarkers* 10.2174/2210309005666151028192843
26. Lampropoulou I, Papagianni A, Stangou M, Didangelos T, Iliadis F, Efstratiadis G. TNF $\alpha$  and microalbuminuria in patients with type 2 diabetes mellitus. *J Diabetes Res.* 2014;2014:394206. doi: 10.1155/2014/394206. Epub 2014 Dec 22.
27. Stangou M, Papagianni A, Bantis C, et al. Detection of multiple cytokines in the urine of patients with focal necrotising glomerulonephritis may predict short and long term outcome of renal function. *Cytokine* 2012;57(1):120-126
28. Bantis C, Heering PJ, Stangou M, Kouri NM, Schwandt C, Memmos D, Rump LC, Ivens K Influence of aldosterone synthase gene C-344T polymorphism on focal segmental glomerulosclerosis. *Nephrology* 2011;16(8):730-5

29. Stangou M, Ekonomidou D, Giamalis P, et al. Steroids and azathioprine in the treatment of IgA nephropathy. *Clin Exp Nephrol* 2011 Jun;15(3):373-380
30. Bili H, Tsolakidis D, Stangou M, Zafrakas M, Pados G, Memmos D, Tarlatzis BC. New insights of osmoregulatory system changes in ovarian hyperstimulation syndrome. *Fertil Steril* 2011:95
31. Stangou M, Bhangal G, Lai PC, Smith J, Keith JC Jr, Boyle JJ, Pusey CD, Cook T, Tam FW. Effect of IL-II on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats. *J Nephrol* 2011;24:106-111
32. Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, Ivens K, Heering PJ. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. *Am J Kidney Dis* 2010;55:259-268.
33. Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D. C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. *Scand J Urol Nephrol* 2008;42(4):373-380.
34. Stangou M, Alexopoulos E, Papagianni A, Pantzaki A, Bantis C, Dovas S, Economidou D, Leontsini M, Memmos D. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. *Nephrology* 2009;14(6):613-620.
35. Anagnostis P, Stangou M, Leontsini M, Athyros VG, Karagiannis. A Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult. *Ren Fail* 2008;30(3):331-334
36. Stangou M, Asimaki A, Bamichas G, et al. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience. *J Nephrol* 2005;18(1):35-44.
37. Zahirieh A, Nesbit MA, Ali A, et al. Functional analysis of a novel GATA3 mutation in a family with the hypoparathyroidism, deafness, and renal dysplasia syndrome. *J Clin Endocrinol Metab* 2005;90(4):2445-2450
38. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. *Ren Fail* 2004;26(4): 453-459
39. Sombolos K, Fragia T K, Bamichas GI, et al. Heparin solution locked in acute hemodialysis catheters: impact on activated partial thromboplastin time. *ASAIO J* 2003;49(3):287-9.



40. Sombolos K, Fragia T, Natse T, et al. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients. *J Nephrol* 2002;15(6):671-675.
41. Christidou F, Bamichas G, Stangou M, Natse T, Kalpakidis V, Sombolos K. Tumoral calcinosis inducing systemic inflammatory response in a hemodialysis patient. *Nephron* 2002;92:497-498
42. Bamichas G, Natse T, Christidou F, Stangou M, Karagianni A, Koukourikos S, Chaidemenos G, Chrysomallis F, Sombolos K. Plasma exchange in patients with toxic epidermal necrolysis. *Ther Apher* 2002;6(3):225-228.
43. Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 2000; 15(9):1348-1356.
44. Alexopoulos E, Papagianni A, Stangou M, Pantzaki A, Papadimitriou M. Adult-onset idiopathic nephrotic syndrome associated with pure diffuse mesangial hypercellularity. *Nephrol Dial Transplant* 2000;15(7):981-987.
45. Dimitriadis A, Antoniou S, Hatzisavvas N, Pastore F, Kaldi I, Stangou M. The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients. *Perit Dial Int.*1993;13:153-158